1
|
Soni D, Sahoo I, Mallya AD, Kamthe P, Sahai A, Goel SK, Kulkarni PS, Dhere RM. Development of competitive inhibition ELISA as an effective potency test to analyze human rabies vaccines and assessment of the antigenic epitope of rabies glycoprotein. J Immunol Methods 2020; 492:112939. [PMID: 33309752 DOI: 10.1016/j.jim.2020.112939] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2020] [Revised: 11/30/2020] [Accepted: 12/01/2020] [Indexed: 11/17/2022]
Abstract
The potency of all modern tissue culture human rabies vaccines is measured based on the National Institute of Health (NIH) potency test that is laborious, time-consuming, involves large test variations and requires sacrifice of large number of animals. To circumvent these limitations, several researchers and WHO expert working groups have discussed development of alternative in vitro methods to replace the NIH potency test. Although several immunochemical methods have been proposed to quantify rabies glycoprotein (G-protein) using multiple murine monoclonal antibodies, we report an In vitro competitive inhibition ELISA (CIA) method based on the use of a neutralizing rabies glycoprotein site III directed novel therapeutic human rabies monoclonal antibody (RAB1) that shows equivalence to the mice NIH potency test in recognition of neutralization site of the glycoprotein. In vitro potency testing of WHO 7th International Standard for rabies vaccine (IS) by CIA using RAB1 and In-house reference standard (IHRS) as a standard to assess its suitability for the assessment of validation parameters showed accurate and precise values with <15% coefficient variance. The method was validated using 5PL standard curve with linearity r2 > 0.98 and LLOQ of 0.125 IU/mL indicating sensitivity of the method. The method was found to be precise, robust and accurate to quantitate intact rabies glycoprotein in final vaccine and showed a strong correlation (Pearson's r = 0.81) with the NIH potency values of licensed Vero cell rabies vaccine. The CIA test using RAB1 was able to accurately quantitate degradation of rabies vaccine and assess loss in antigenicity of lyophilized and reconstituted liquid rabies vaccine under thermal stress conditions. The method was able to differentiate between potent and reduced potency vaccine samples. The new in vitro competitive inhibition ELISA method using RAB1 thus can be a valid alternative to the NIH test.
Collapse
Affiliation(s)
- Dipen Soni
- Research and Development Department, Serum Institute of India Pvt. Ltd, Hadapsar, Pune 410028, Maharashtra, India
| | - Itishree Sahoo
- Research and Development Department, Serum Institute of India Pvt. Ltd, Hadapsar, Pune 410028, Maharashtra, India
| | - Asha D Mallya
- Research and Development Department, Serum Institute of India Pvt. Ltd, Hadapsar, Pune 410028, Maharashtra, India.
| | - Praveen Kamthe
- Research and Development Department, Serum Institute of India Pvt. Ltd, Hadapsar, Pune 410028, Maharashtra, India
| | - Ashish Sahai
- Research and Development Department, Serum Institute of India Pvt. Ltd, Hadapsar, Pune 410028, Maharashtra, India
| | - Sunil Kumar Goel
- Research and Development Department, Serum Institute of India Pvt. Ltd, Hadapsar, Pune 410028, Maharashtra, India
| | - Prasad S Kulkarni
- Research and Development Department, Serum Institute of India Pvt. Ltd, Hadapsar, Pune 410028, Maharashtra, India
| | - Rajeev M Dhere
- Research and Development Department, Serum Institute of India Pvt. Ltd, Hadapsar, Pune 410028, Maharashtra, India
| |
Collapse
|
2
|
Olayan E, El-Khadragy M, Mohamed AF, Mohamed AK, Shebl RI, Yehia HM. Evaluation of Different Stabilizers and Inactivating Compounds for the Enhancement of Vero Cell Rabies Vaccine Stability and Immunogenicity: In Vitro Study. BIOMED RESEARCH INTERNATIONAL 2019; 2019:4518163. [PMID: 31008105 PMCID: PMC6441502 DOI: 10.1155/2019/4518163] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/03/2018] [Accepted: 02/10/2019] [Indexed: 12/25/2022]
Abstract
Inactivation of rabies virus is essential for rabies vaccine preparation where the inactivating compound that is currently recommended for rabies vaccine preparation is β-propiolactone (β-PL). This compound is considered better than phenol and formalin but it is expensive and potentially carcinogenic. Data revealed that Ascorbic acid (AA) with cupric ions could yield complete and irreversible inactivation of rabies virus without adversely affecting its antigenicity. Additionally, the results of testing the vaccine potency with the selected inactivating compounds were comparable (P<0.05), and ED50 was higher than the recommended World Health Organization (WHO) limits. The use of HemaGel (plasma substitute) for testing vaccine stabilization was compared with the currently used vaccine stabilizers (human albumin and lactose). HemaGel yielded better stability than the other tested stabilizers. Monitoring of cellular and humoral immune responses indicated that both the total IgG level against rabies vaccine and the IFN and IL5 levels obtained with the HemaGel-stabilized vaccines were higher than those obtained with human albumin- and lactose-stabilized vaccine candidates.
Collapse
Affiliation(s)
- Ebtesam Olayan
- Chair Vaccines Research of Infectious Diseases, Faculty of Science, Zoology Department, King Saud University, Riyadh, Saudi Arabia
| | - Manal El-Khadragy
- Chair Vaccines Research of Infectious Diseases, Faculty of Science, Zoology Department, King Saud University, Riyadh, Saudi Arabia
- Zoology Department, College of Science, King Saud University, Riyadh, Saudi Arabia
- Department of Zoology and Entomology, Faculty of Science, Helwan University, Cairo, Egypt
| | - Aly Fahmy Mohamed
- Holding Company for Production of Sera, Vaccines and Drugs (VACSEA), Egypt
| | | | - Rania Ibrahim Shebl
- Department of Microbiology and Immunology, Faculty of Pharmacy, Ahram Canadian University (ACU), Cairo, Egypt
| | - Hany M. Yehia
- Department of Food Science and Nutrition, College of Food and Agricultural Sciences, King Saud University, Saudi Arabia
- Department of Food Science and Nutrition, Faculty of Home Economics, Helwan University, Egypt
| |
Collapse
|
3
|
Wang Z, Sun Y, Wu X, Carroll DS, Lv W, You L, Ji Y, Shi J, Yan J, Xu G, Meng S. Development of a relative potency test using ELISA for human rabies vaccines. Biologicals 2018; 55:59-62. [DOI: 10.1016/j.biologicals.2018.06.003] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2018] [Revised: 06/14/2018] [Accepted: 06/26/2018] [Indexed: 11/15/2022] Open
|
4
|
Aavula SM, Abhinay G, Nimmagadda SV, Maithal K. A novel in vitro ELISA for estimation of glycoprotein content in human rabies vaccines. J Immunoassay Immunochem 2017; 38:400-410. [PMID: 28436708 DOI: 10.1080/15321819.2017.1295056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
In vitro methods for quantification of immunodominant glycoprotein in the rabies vaccine formulations serve as good alternative to the cumbersome and variable mice potency assay as a batch release test for the vaccine. The present study presents the development of a sandwich ELISA with optimal concentrations of a high affinity recombinant diabody (D06) and a specific monoclonal antibody (M5B4) against rabies glycoprotein for its quantification in the vaccine formulations. The glycoprotein estimate correlated linearly (r2 = 0.8) to the in vivo potency estimate for the vaccine formulations. This ELISA promises a good forecast of the mice potency values and thereby can serve as a simple, yet effective batch release test for the rabies vaccines replacing the in vivo assay.
Collapse
Affiliation(s)
- Shukra M Aavula
- a Research and Development Centre , Indian Immunologicals Limited, Rakshapuram, Gachibowli , Hyderabad , Telangana , India
| | - Gontu Abhinay
- a Research and Development Centre , Indian Immunologicals Limited, Rakshapuram, Gachibowli , Hyderabad , Telangana , India
| | - Sridevi V Nimmagadda
- a Research and Development Centre , Indian Immunologicals Limited, Rakshapuram, Gachibowli , Hyderabad , Telangana , India
| | - Kapil Maithal
- a Research and Development Centre , Indian Immunologicals Limited, Rakshapuram, Gachibowli , Hyderabad , Telangana , India
| |
Collapse
|
5
|
Chabaud-Riou M, Moreno N, Guinchard F, Nicolai MC, Niogret-Siohan E, Sève N, Manin C, Guinet-Morlot F, Riou P. G-protein based ELISA as a potency test for rabies vaccines. Biologicals 2017; 46:124-129. [DOI: 10.1016/j.biologicals.2017.02.002] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2016] [Revised: 01/27/2017] [Accepted: 02/03/2017] [Indexed: 10/20/2022] Open
|
6
|
Takayama-Ito M, Lim CK, Nakamichi K, Kakiuchi S, Horiya M, Posadas-Herrera G, Kurane I, Saijo M. Reduction of animal suffering in rabies vaccine potency testing by introduction of humane endpoints. Biologicals 2016; 46:38-45. [PMID: 28040390 DOI: 10.1016/j.biologicals.2016.12.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2016] [Accepted: 12/20/2016] [Indexed: 10/20/2022] Open
Abstract
Potency controls of inactivated rabies vaccines for human use are confirmed by the National Institutes of Health challenge test in which lethal infection with severe neurological symptoms should be observed in approximately half of the mice inoculated with the rabies virus. Weight loss, decreased body temperature, and the presence of rabies-associated neurological signs have been proposed as humane endpoints. The potential for reduction of animal suffering by introducing humane endpoints in the potency test for inactivated rabies vaccine for human use was investigated. The clinical signs were scored and body weight was monitored. The average times to death following inoculation were 10.49 and 10.99 days post-inoculation (dpi) by the potency and challenge control tests, respectively, whereas the average times to showing Score-2 signs (paralysis, trembling, and coma) were 6.26 and 6.55 dpi, respectively. Body weight loss of more than 15% appeared at 5.82 and 6.42 dpi. The data provided here support the introduction of obvious neuronal signs combined with a body weight loss of ≥15% as a humane endpoint to reduce the time of animal suffering by approximately 4 days.
Collapse
Affiliation(s)
| | - Chang-Kweng Lim
- Department of Virology I, National Institute of Infectious Diseases, Japan
| | - Kazuo Nakamichi
- Department of Virology I, National Institute of Infectious Diseases, Japan
| | - Satsuki Kakiuchi
- Department of Virology I, National Institute of Infectious Diseases, Japan
| | - Madoka Horiya
- Department of Virology I, National Institute of Infectious Diseases, Japan
| | | | - Ichiro Kurane
- Department of Virology I, National Institute of Infectious Diseases, Japan
| | - Masayuki Saijo
- Department of Virology I, National Institute of Infectious Diseases, Japan
| |
Collapse
|
7
|
Servat A, Kempff S, Brogat V, Litaize E, Schereffer JL, Cliquet F. A step forward in the quality control testing of inactivated rabies vaccines - extensive evaluation of European vaccines by using alternative methods to the in vivo potency tests. Altern Lab Anim 2015; 43:19-27. [PMID: 25802995 DOI: 10.1177/026119291504300106] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The mouse challenge test still remains the reference method for the potency determination of human and animal inactivated rabies vaccines, and it is still widely used throughout the world. This test suffers from many disadvantages - it is expensive and time consuming, uses a large number of mice, causes significant animal distress, and suffers from high variability. Recently, the European Pharmacopoeia has recognised the use of a serological potency assay (SPA) as an alternative method to the challenge test. This new test is based on the determination of rabies neutralising antibody titres in vaccinated mice, by using the modified Rapid Fluorescent Focus Inhibition Test (mRFFIT). With the objective of adopting this new method for the batch release of inactivated rabies vaccines, we evaluated its performance on a large collection of rabies vaccines currently assessed in our laboratory. The Fluorescent Antibody Virus Neutralisation test (FAVNt) was used in parallel with the mRFFIT, and the results were compared to the mouse challenge test. Our results demonstrate that the SPA is capable of estimating the potency of vaccines formulated with a potency margin well above the minimum of 1IU/dose. For low potency vaccines, this new method demonstrated some limitations, due to the recurrent invalidation of the assay. We have also demonstrated the superior sensitivity of the FAVNt when compared to the mRFFIT, and the importance of minimising the risk of detecting non-responders in vaccinated mice.
Collapse
Affiliation(s)
- Alexandre Servat
- French Agency for Food, Environmental and Occupational Health Safety (ANSES), Nancy Laboratory for Rabies and Wildlife (EU Reference Laboratory for Rabies, EU Reference Laboratory for Rabies Serology, WHO Collaborating Centre for Research and Management in Zoonoses Control, OIE Reference Laboratory for Rabies), Malzéville, France
| | - Sébastien Kempff
- French Agency for Food, Environmental and Occupational Health Safety (ANSES), Nancy Laboratory for Rabies and Wildlife (EU Reference Laboratory for Rabies, EU Reference Laboratory for Rabies Serology, WHO Collaborating Centre for Research and Management in Zoonoses Control, OIE Reference Laboratory for Rabies), Malzéville, France
| | - Valère Brogat
- French Agency for Food, Environmental and Occupational Health Safety (ANSES), Nancy Laboratory for Rabies and Wildlife (EU Reference Laboratory for Rabies, EU Reference Laboratory for Rabies Serology, WHO Collaborating Centre for Research and Management in Zoonoses Control, OIE Reference Laboratory for Rabies), Malzéville, France
| | - Estelle Litaize
- French Agency for Food, Environmental and Occupational Health Safety (ANSES), Nancy Laboratory for Rabies and Wildlife (EU Reference Laboratory for Rabies, EU Reference Laboratory for Rabies Serology, WHO Collaborating Centre for Research and Management in Zoonoses Control, OIE Reference Laboratory for Rabies), Malzéville, France
| | - Jean-Luc Schereffer
- French Agency for Food, Environmental and Occupational Health Safety (ANSES), Nancy Laboratory for Rabies and Wildlife (EU Reference Laboratory for Rabies, EU Reference Laboratory for Rabies Serology, WHO Collaborating Centre for Research and Management in Zoonoses Control, OIE Reference Laboratory for Rabies), Malzéville, France
| | - Florence Cliquet
- French Agency for Food, Environmental and Occupational Health Safety (ANSES), Nancy Laboratory for Rabies and Wildlife (EU Reference Laboratory for Rabies, EU Reference Laboratory for Rabies Serology, WHO Collaborating Centre for Research and Management in Zoonoses Control, OIE Reference Laboratory for Rabies), Malzéville, France
| |
Collapse
|
8
|
Abstract
Inactivated vaccines have been used for over a century to induce protection against viral pathogens. This established approach of vaccine production is relatively straightforward to achieve and there is an augmented safety profile as compared to their live counterparts. Today, there are six viral pathogens for which licensed inactivated vaccines are available with many more in development. Here, we describe the principles of viral inactivation and the application of these principles to vaccine development. Specifically emphasized are the manufacturing procedure and the accompanying assays, of which assays used for monitoring the inactivation process and preservation of neutralizing epitopes, are pivotal. Novel inactivated vaccines in development and the hurdles they face for licensure are also discussed as well as the (dis)advantages of inactivation over the other vaccine production methodologies.
Collapse
|
9
|
Gibert R, Alberti M, Poirier B, Jallet C, Tordo N, Morgeaux S. A relevant in vitro ELISA test in alternative to the in vivo NIH test for human rabies vaccine batch release. Vaccine 2013; 31:6022-9. [DOI: 10.1016/j.vaccine.2013.10.019] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2013] [Revised: 09/26/2013] [Accepted: 10/04/2013] [Indexed: 11/28/2022]
|
10
|
Abhinay G, Dessain S, Srikanth A, Senthilkumar RL, Vidyasagar P, Praveen A, Chandrasekhar Reddy RV, Swapna Reddy E, Rajendra L. A novel site-II directed glycoprotein estimation ELISA to aid rabies vaccine manufacture for veterinary and human use. Vaccine 2013; 32:209-13. [PMID: 24262315 DOI: 10.1016/j.vaccine.2013.11.026] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2013] [Revised: 10/25/2013] [Accepted: 11/06/2013] [Indexed: 11/25/2022]
Abstract
Although the World Health Organization recommends the use of in vitro techniques to qualify rabies vaccine lot release, very limited proposals have been made to arrive at a harmonized approach for wide scale usage. The present study proposed and evaluated the use of a novel avidin-biotin ELISA as an alternative to these in vivo tests in rabies vaccine manufacture. This assay utilized a neutralizing pan reactive monoclonal antibody (mAb) reactive with the conserved site-II of the natively folded rabies glycoprotein. Linear regression analysis of the in vitro glycoprotein estimates with the in vivo potency values, showed a good correlation (r(2)=0.8) with veterinary vaccines, but a poor correlation (r(2)=0.2) with human vaccines. However, we could qualitatively arrive at cut-off glycoprotein estimates from the ELISA, above which all the vaccines were declared to be protective by mouse challenge studies (>2.5IU/dose).
Collapse
Affiliation(s)
- Gontu Abhinay
- Indian Immunologicals Limited, Gachibowli, Hyderabad 500032, Andhra Pradesh, India
| | - Scott Dessain
- Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA
| | - Adabala Srikanth
- Indian Immunologicals Limited, Gachibowli, Hyderabad 500032, Andhra Pradesh, India
| | - R L Senthilkumar
- Indian Immunologicals Limited, Gachibowli, Hyderabad 500032, Andhra Pradesh, India
| | - Pitta Vidyasagar
- Indian Immunologicals Limited, Gachibowli, Hyderabad 500032, Andhra Pradesh, India
| | - Alagangula Praveen
- Indian Immunologicals Limited, Gachibowli, Hyderabad 500032, Andhra Pradesh, India
| | | | - Erri Swapna Reddy
- Indian Immunologicals Limited, Gachibowli, Hyderabad 500032, Andhra Pradesh, India
| | - Lingala Rajendra
- Indian Immunologicals Limited, Gachibowli, Hyderabad 500032, Andhra Pradesh, India.
| |
Collapse
|
11
|
Delrue I, Verzele D, Madder A, Nauwynck HJ. Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges. Expert Rev Vaccines 2012; 11:695-719. [PMID: 22873127 DOI: 10.1586/erv.12.38] [Citation(s) in RCA: 115] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The aim of this review is to make researchers aware of the benefits of an efficient quality control system for prediction of a developed vaccine's efficacy. Two major goals should be addressed when inactivating a virus for vaccine purposes: first, the infectious virus should be inactivated completely in order to be safe, and second, the viral epitopes important for the induction of protective immunity should be conserved after inactivation in order to have an antigen of high quality. Therefore, some problems associated with the virus inactivation process, such as virus aggregate formation, protein crosslinking, protein denaturation and degradation should be addressed before testing an inactivated vaccine in vivo.
Collapse
Affiliation(s)
- Iris Delrue
- Laboratory of Virology, Department of Virology, Parasitology and Immunology, Ghent University, Merelbeke, Belgium
| | | | | | | |
Collapse
|
12
|
McFarland R, Verthelyi D, Casey W, Arciniega J, Isbrucker R, Schmitt M, Finn T, Descamps J, Horiuchi Y, Sesardic D, Stickings P, Johnson NW, Lipscomb E, Allen D. Non-animal replacement methods for human vaccine potency testing: state of the science and future directions. PROCEDIA IN VACCINOLOGY 2011; 5:16-32. [PMID: 32288913 PMCID: PMC7129268 DOI: 10.1016/j.provac.2011.10.002] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
NICEATM and ICCVAM convened an international workshop to review the state of the science of human and veterinary vaccine potency and safety testing methods, and to identify opportunities to advance new and improved methods that can further reduce, refine, and replace animal use. This report addresses methods and strategies identified by workshop participants for replacement of animals used for potency testing of human vaccines. Vaccines considered to have the highest priority for future efforts were (1) vaccines for which antigen quantification methods are already developed but not validated, (2) vaccines/components that require the largest number of animals, (3) vaccines that require an in vivo challenge test, and (4) vaccines with in vivo tests that are highly variable and cause a significant number of invalid tests. Vaccine potency tests identified as the highest priorities for replacement were those for diphtheria and tetanus, pertussis (whole cell and acellular), rabies, anthrax, polio vaccine (inactivated) and complex combination vaccines based on DT or DTwP/aP. Research into understanding the precise mechanism of protection afforded by vaccines and the identification of clinically relevant immunological markers are needed to facilitate the successful implementation of in vitro testing alternatives. This report also identifies several priority human vaccines and associated research objectives that are necessary to successfully implement in vitro vaccine potency testing alternatives.
Collapse
Affiliation(s)
- Richard McFarland
- United States Food and Drug Administration- Center for Biologics Evaluation and Research, Rockville, Maryland, USA
| | - Daniela Verthelyi
- United States Food and Drug Administration- Center for Drug Evaluation and Research, Silver Spring, Maryland, USA
| | - Warren Casey
- National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods, Division of the National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA
| | - Juan Arciniega
- United States Food and Drug Administration- Center for Biologics Evaluation and Research, Rockville, Maryland, USA
| | - Richard Isbrucker
- Health Canada, Center for Vaccine Evaluation, Ottawa, Ontario, Canada
| | - Michael Schmitt
- United States Food and Drug Administration- Center for Biologics Evaluation and Research, Rockville, Maryland, USA
| | - Theresa Finn
- United States Food and Drug Administration- Center for Biologics Evaluation and Research, Rockville, Maryland, USA
| | | | | | - Dorothea Sesardic
- National Institute for Biological Standards and Control, Health Protection Agency, Hertfordshire, United Kingdom
| | - Paul Stickings
- National Institute for Biological Standards and Control, Health Protection Agency, Hertfordshire, United Kingdom
| | - Nelson W Johnson
- Integrated Laboratory Systems, Inc., Research Triangle Park, North Carolina, USA
| | - Elizabeth Lipscomb
- Integrated Laboratory Systems, Inc., Research Triangle Park, North Carolina, USA
| | - David Allen
- Integrated Laboratory Systems, Inc., Research Triangle Park, North Carolina, USA
| |
Collapse
|
13
|
Delrue I, Delputte PL, Nauwynck HJ. Assessing the functionality of viral entry-associated domains of porcine reproductive and respiratory syndrome virus during inactivation procedures, a potential tool to optimize inactivated vaccines. Vet Res 2009; 40:62. [PMID: 19674538 DOI: 10.1051/vetres/2009047] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2009] [Accepted: 08/11/2009] [Indexed: 11/14/2022] Open
Abstract
Porcine reproductive and respiratory syndrome virus (PRRSV) causes severe economic losses in the pig industry worldwide. Currently, vaccines based on inactivated PRRSV provide limited protection of pigs against infection, most likely because viral epitopes associated with the induction of neutralizing antibodies are not or poorly conserved during inactivation. To analyze the effect of inactivation procedures on the interaction of PRRSV with receptors involved in virus entry, a new assay was set up in this study. Viral entry-associated domains are most likely important for the induction of neutralizing antibodies, since neutralizing antibodies block interaction of PRRSV with cellular receptors. To investigate the interaction of PRRSV with the cellular receptors upon different inactivation procedures, attachment to and internalization of inactivated PRRSV into macrophages were monitored. AT-2 could not inactivate PRRSV completely and is therefore not useful for vaccine development. PRRSV inactivated with ultraviolet light, binary ethyleneimine and gamma irradiation, which all mainly have an effect at the genomic level, showed no difference compared to control live virus at all levels of virus entry, whereas PRRSV treated with formaldehyde, glutaraldehyde and pH changes, which all have a modifying effect on proteins, was not able to internalize into macrophages anymore. These results suggest that inactivation with methods with a main effect on the viral genome preserve PRRSV entry-associated domains and are useful for future development of an effective inactivated vaccine against PRRSV. Although PRRSV incubation at 37 degrees C can completely inactivate PRRSV with preservation of entry-associated domains, this method is not recommended for vaccine development, since the mechanism is yet unknown.
Collapse
Affiliation(s)
- Iris Delrue
- Department of Virology, Parasitology and Immunology, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium
| | | | | |
Collapse
|
14
|
Hendriksen CFM. Replacement, reduction and refinement alternatives to animal use in vaccine potency measurement. Expert Rev Vaccines 2009; 8:313-22. [PMID: 19249973 DOI: 10.1586/14760584.8.3.313] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Models to measure potency in vaccine research and development and preclinical testing are frequently based on an immunization-challenge procedure in laboratory animals. These models have proven to be very instrumental in scientifically underpinning the correlation of protection of selected vaccine antigens and their efficacy. In vivo models in vaccine research and development are, for the time being, irreplaceable, although significant progress has been made in using in vitro prescreening tests to evaluate particular immunological parameters. For a long time, in vivo potency tests have been similarly relevant for routine vaccine lot-release testing. The design of a potency test, defined in most pharmacopeias, relied on a direct or indirect-challenge procedure in laboratory animals. For various reasons, there now is an increased interest in the development of alternatives to the current in vivo potency tests. Animal models have their limitations, with respect to their relevance, reliability, costs and moral acceptability. All alternative approaches have in common that they ultimately result in a refinement, reduction or replacement in the use of animals. The new models range from modifications of the existing in vivo test procedure (e.g., use of humane end points or serology instead of challenge) to in vitro antigen-quantification tests. A new paradigm in quality control of vaccines is the consistency approach. This approach is state-of-the-art in quality control of the new-generation vaccines and it is now finding its way into the quality control of traditional vaccines. The consistency approach implies the use of a set of parameters to constitute a product profile, which is monitored throughout production, and which guarantees that each lot released is similar to a manufacturer-specific vaccine of proven clinical efficacy and safety. Consistency relies heavily on the implementation of quality systems, such as good manufacturing practice and quality assurance, and on the use of in vitro analytical tools, such as immunochemical and physicochemical tests.
Collapse
|
15
|
Krämer B, Schildger H, Behrensdorf-Nicol HA, Hanschmann KM, Duchow K. The rapid fluorescent focus inhibition test is a suitable method for batch potency testing of inactivated rabies vaccines. Biologicals 2009; 37:119-26. [PMID: 19181541 DOI: 10.1016/j.biologicals.2009.01.001] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2008] [Revised: 10/30/2008] [Accepted: 01/09/2009] [Indexed: 11/19/2022] Open
Abstract
The European Pharmacopoeia proposes two methods for potency determination of inactivated rabies vaccines for veterinary use: The first one is a classical mouse challenge test, which is imprecise, time-consuming, and causes severe distress to the test animals. Alternatively, the potency may be determined serologically by measuring the neutralizing antibody titers induced after vaccination of mice by using a rapid fluorescent focus inhibition test (RFFIT). Although this method is faster and less painful for the animals, it is not widely used yet, and only little data exist concerning the comparability of both methods. We have therefore performed a comparative study, in which we demonstrated a good correlation between the challenge test results and the mean titers determined by RFFIT. Furthermore, all vaccine batches failing the challenge test were also recognized as insufficient in the serological assay. This publication further describes the influence of different vaccine administration routes on the resulting antibody titers, and it proposes various modifications to the serological assay protocol which could improve its overall practicability. Finally, we recommend that the serological assay be used for the potency testing of inactivated rabies vaccines.
Collapse
Affiliation(s)
- B Krämer
- Paul-Ehrlich-Institut, Paul-Ehrlich-Strasse 51-59, Langen, Germany.
| | | | | | | | | |
Collapse
|
16
|
Mousli M, Turki I, Kharmachi H, Saadi M, Dellagi K. Recombinant single-chain Fv antibody fragment–alkaline phosphatase conjugate: A novel in vitro tool to estimate rabies viral glycoprotein antigen in vaccine manufacture. J Virol Methods 2007; 146:246-56. [PMID: 17845821 DOI: 10.1016/j.jviromet.2007.07.015] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2007] [Revised: 07/02/2007] [Accepted: 07/09/2007] [Indexed: 10/22/2022]
Abstract
The purpose of this study was to design a novel in vitro tool by using recombinant protein technology to qualify the whole reagent preparation procedure, to be used to quantify rabies viral antigen preparation in a simple and rapid format for potency control of rabies vaccines. 50AD1 is a neutralizing monoclonal antibody directed against the rabies virus glycoprotein that binds to native conformational antigenic site III. In the present study, the DNA fragments encoding the variable domains of 50AD1 were inserted into a prokaryotic expression vector so as to produce a single-chain Fv antibody fragment (scFv) genetically fused to the bacterial alkaline phosphatase (AP). The recombinant fusion protein preserved both the AP enzymatic activity and the antigen-binding activity against the rabies virus glycoprotein nearly identical to the parental antibody, and was used successfully in different assays including ELISA, dot-blot and cell culture tests. The present study shows that the genetic fusion protein provides a new tool for one-step rabies virus immunodetection, which can be produced in homogeneous bifunctional reagent, easily, quickly and reproducibly. In addition, this recombinant immunoconjugate is a promising alternative reagent for applications involving immunodetection, it presents a similar sensitivity and specificity to that obtained with classical reagents.
Collapse
Affiliation(s)
- Mohamed Mousli
- Laboratoire d'Immunopathologie, Vaccinologie et Génétique Moléculaire, Institut Pasteur de Tunis, 13 Place Pasteur BP74, 1002 Tunis-Belvédère, Tunisia.
| | | | | | | | | |
Collapse
|
17
|
|
18
|
Wunderli PS, Dreesen DW, Miller TJ, Baer GM. The rabies peripheral challenge test: More accurate determination of vaccine potency. Vaccine 2006; 24:7115-23. [PMID: 16919854 DOI: 10.1016/j.vaccine.2006.06.078] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2005] [Revised: 04/28/2006] [Accepted: 06/30/2006] [Indexed: 10/24/2022]
Abstract
The National Institutes of Health (NIH) rabies vaccine potency test is used internationally for evaluating the efficacy of inactivated rabies vaccines, despite concerns about its methods. An alternative test has been developed, using a simplified in vivo method for rabies vaccine testing which has several advantages over the currently recommended method of efficacy testing. The rabies peripheral challenge test more closely models practical vaccine application in target species; decreases the observed effect of vaccine virus strain in testing results and allows sensitive analysis of vaccine and production lot testing.
Collapse
Affiliation(s)
- Peter S Wunderli
- ImmunoGen Inc., 128 Sidney Street, Cambridge, MA 02139-4239, USA.
| | | | | | | |
Collapse
|
19
|
Cardoso TC, Silva LHQD, Albas A, Ferreira HL, Perri SHV. Rabies neutralizing antibody detection by indirect immunperoxidase serum neutralization assay performed on chicken embryo related cell line. Mem Inst Oswaldo Cruz 2004; 99:531-4. [PMID: 15543419 DOI: 10.1590/s0074-02762004000500013] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
The aim of this study was to evaluate the indirect immunoperoxidase virus neutralization (IPVN) and mouse neutralization test (MNT) to detect antibodies against rabies virus from vaccinated dogs and cattle. The IPVN was set up for the ability to measure 0.5 International Units/ml (IU) of antibody required by the World Health Organization and the Office International des Epizooties as the minimum response for proof of rabies immunization. IPVN was developed and standardized in chicken embryo related (CER) cell line when 141 dog and 110 cattle sera were applied by serial five-fold dilutions (1:5, 1:25, 1:125) as well as the positive and negative reference controls, all added in four adjacent wells, of 96-well microplates. A 50 microl amount of CVS32 strain dilution containing 50-200 TCID50/ml was mixed to each serum dilution, and after 90 min 50 microl of 3 x 10(5) cells/mlcell suspension added to each well. After five days of incubation, the monolayers were fixed and the IPVN test performed. The correlation coefficient between the MNT and IPVN performed in CER cells was r = 0.9949 for dog sera (n = 100) and r = 0.9307 for cattle sera (n = 99), as well as good specificity (94.7%), sensitivity (87.5%), and agreement (96.6%) were also obtained. IPVN technique can adequately identify vaccinated and unvaccinated animals, even from low-responding vaccinated animals, with the advantage of low cost and faster then MNT standard test.
Collapse
Affiliation(s)
- Tereza Cristina Cardoso
- Departamento de Apoio, Produção e Saúde Animal, Curso de Medicina Veterinária, Unesp, Campus de Araçatuba, Rua Clóvis Pestana 793, 16050-680 Araçatuba, SP, Brazil.
| | | | | | | | | |
Collapse
|
20
|
Maas RA, Komen M, van Diepen M, Oei HL, Claassen IJTM. Correlation of haemagglutinin-neuraminidase and fusion protein content with protective antibody response after immunisation with inactivated Newcastle disease vaccines. Vaccine 2003; 21:3137-42. [PMID: 12804840 DOI: 10.1016/s0264-410x(03)00249-4] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The correlation between the antigen content of inactivated Newcastle disease (ND) oil emulsion-vaccines and the serological response after immunisation was studied. The haemagglutinin-neuraminidase (HN) and fusion (F) proteins of Newcastle disease virus (NDV) were quantified in 33 inactivated oil-adjuvanted ND vaccines using isopropylmyristate (IPM)-extraction and antigen ELISAs. These commercial vaccines differed in NDV-vaccine strain, the method applied to inactivate the vaccine virus, the vaccine valence and the composition of the oil emulsions. Large differences, up to 100-fold, in the antigen quantities present in different vaccines were found. The NDV-HN content and the NDV-F content of the vaccines both highly correlated with the haemagglutination-inhibiting (HI) antibody titres after immunisation. These correlation's were found over a 10,000-fold range of applied antigen. The antigen content of the oil emulsion-vaccines also highly correlated with virus neutralising antibody titres. The presence of serum HI antibody titres in individual specific pathogens free (SPF)-chickens after immunisation with inactivated ND vaccines was highly indicative for clinical protection against challenge with the virulent NDV-Herts strain. Our results are the first to demonstrate that the protective serological response after immunisation highly correlates with the antigen content of oil-adjuvanted vaccines.
Collapse
Affiliation(s)
- R A Maas
- Central Institute of Animal Disease Control Lelystad (CIDC-Lelystad), P.O. Box 2004, 8203 AA, Lelystad, The Netherlands.
| | | | | | | | | |
Collapse
|
21
|
Abstract
The use of potency control testing is a valuable tool for testing the actual relative strength of manufactured assembly lots of vaccine. Biological-based manufacturing methods are inherently variable and potency testing is a tool to ensure lot-to-lot consistency of commercial vaccines. A strong historical link to clinical efficacy has been established where correlation to efficacy and adequate test validation have been achieved. The link to immunogenicity and efficacy has traditionally been strongest with attenuated vaccines and toxoids. Control potency test failure does predict that a serial or batch of vaccine would most likely provide insufficient immunogenicity in typical field applications. Because of the complexity of pathogenic processes and associated immune responses, potency tests may not always directly predict the effectiveness of a vaccine. Thus, vaccines that pass control potency testing may not always provide adequate efficacy. This is particularly true of adjuvanted, inactivated vaccines. In the development of vaccine formulations and control tests for vaccines, the nature of the desired protective immune responses to the targeted pathogen (when known) should be considered. These considerations could provide better alternatives in the assays chosen as correlates of immunity and may more accurately predict efficacy and assure batch-to-batch consistency. Also, the effects of the dose and duration of antigen exposure as well as the nature of antigen presentation and generation of extrinsic cytokines could be characterised and correlated to vaccine potency as additional indicators of vaccine efficacy.
Collapse
Affiliation(s)
- David Scott McVey
- Biologicals Development, Veterinary Medicine Research and Development, Pfizer Animal Health, Pfizer, Inc., Eastern Point Road, 8118D-2001, Groton, CT 06340, USA.
| | | | | |
Collapse
|
22
|
Fournier-Caruana J, Poirier B, Haond G, Jallet C, Fuchs F, Tordo N, Perrin P. Inactivated rabies vaccine control and release: use of an ELISA method. Biologicals 2003; 31:9-16. [PMID: 12623055 DOI: 10.1016/s1045-1056(02)00070-2] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
Abstract
Quality control of human rabies vaccines performed by National Control Laboratories (NCLs) prior to marketing vaccines batches requires in vivo and in vitro potency assays as requested by the relevant European Pharmacopoeia monographs, OMCLs guidelines and WHO technical recommendations. The aim of the present study was to check the suitability of an enzyme-linked immunosorbent assay (ELISA) using a virus neutralizing monoclonal antibody, directed to the rabies virus glycoprotein, to monitor the consistency of the lot to lot rabies vaccines production. Furthermore, this work was implemented to establish in house specifications for the glycoprotein content.
Collapse
Affiliation(s)
- Jacqueline Fournier-Caruana
- Agence Française de Sécurité Sanitaire des Produits de Santé, Direction des Laboratoires et des Contrôles, 321 avenue Jean Jaurès, 69007 Lyon, France
| | | | | | | | | | | | | |
Collapse
|
23
|
Katayama S, Yamanaka M, Ota S, Shimizu Y. A new quantitative method for rabies virus by detection of nucleoprotein in virion using ELISA. J Vet Med Sci 1999; 61:411-6. [PMID: 10342293 DOI: 10.1292/jvms.61.411] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
We have developed a new quantitative method for rabies virus (RV) detection using enzyme-linked immunosorbent assay (ELISA). The method named N-ELISA was based on the quantitation of nucleoprotein (N) in RV virions captured by RV-specific polyclonal antibodies on an ELISA plate. Both infective and defective interfering (DI) particles of RV could be detected by this method. When viruses were propagated in a medium of pH 7.4 adjusted with 7% NaHCO3, N-ELISA could detect them with titers of more than 10(6) pfu/ml, though the result did not correlate highly with that of the infectivity assay. The reason for this was considered to be that RVs included spikeless and damaged particles which were produced under conditions of low or high pH. However, in the time course of virus yield, titers of N-ELISA correlated well with those of the infectivity assay.
Collapse
|